cell-based assays | GenomeWeb

cell-based assays

The company plans to use the funds to support the worldwide launch of its commercial platform for propagation and gene editing in cell types that are difficult to transfect.

The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.

Analysis of a gene associated with basal progenitor cell expansions in the brain suggests a single splice site change led to human-specific forms of the gene transcript.

Notable is adopting Labcyte's Echo acoustic liquid handling platform to screen cancer patients' tumor cells for response to individual and combination therapies.

Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.

Cambridge Bioscience will exclusively distribute the Xcell platform in the UK and BioStream will disburse the system in Japan.

Fluidigm Polaris

At AGBT, Fluidigm showcased the Polaris system for integrated single-cell analysis and new applications for the C1, including high-throughput RNA-seq and protein analysis.

NEW YORK (GenomeWeb) – Japanese stem cell products company Reprocell said today that it has purchased 3D cell culture firm Reinnervate and US genomics services firm BioServe.

Exagen Raises $3.95M

NEW YORK (GenomeWeb) – Rheumatology and autoimmune diagnostics firm Exagen Diagnostics has raised $3.95 million, it said in a regulatory document on Monday.

Pages

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.